James O. Jones
0000-0002-2194-4903
Publication & Citation Trends
Publications
50 total
Peripheral blood correlates of outcomes with adjuvant tremelimumab plus durvalumab for patients with renal cell carcinoma at high or intermediate risk of relapse: Initial results from the TransRAMPART study.
Cited by 0
Semantic Scholar
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarised pyruvate MRI
Cited by 0
Semantic Scholar
36International neoadjuvant kidney cancer consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer
Cited by 0
Semantic Scholar
Abstract 1103: Multi-modal machine learning identifies predictive biomarkers of response to neoadjuvant axitinib in renal cell carcinoma with venous tumor thrombus
Cited by 0
Semantic Scholar
Abstract CT175: Neoadjuvant olaparib and cediranib in renal cancer: Outcomes of the WIndow-of-opportunity in REnal cancer (WIRE) Trial
Cited by 0
Semantic Scholar
10Investigating the mechanisms of neoadjuvant olaparib and cediranib in renal cancer: results of arms 1 to 3 of the WIndow of opportunity in REnal cancer (WIRE) clinical trial
Cited by 0
Semantic Scholar
75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer OA
Cited by 1
Semantic Scholar
Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
Cited by 5
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(24)
Renal and related cancers
(12)
Cancer Immunotherapy and Biomarkers
(10)
Cancer Genomics and Diagnostics
(7)
Immunotherapy and Immune Responses
(5)
Affiliations
MRC Laboratory of Molecular Biology
University of Cambridge
Cancer Research UK
Cambridge University Hospitals NHS Foundation Trust
National Institute for Health Research